- S41 -

Overwhelming demand for transformative GLP1 agonists like Ozempic and Mounjaro has led to widespread compounding and a boom in counterfeiting. Several states are trying to reduce healthcare costs by importing medicine from countries where it costs less but this is a deeply flawed policy proposal. Pharmacy Benefit Managers underreimbursements make pharmacies perfect targets for counterfeitersand make the U. S.